Festival of Biologics
Agenda 2024
Our agenda is expertly curated by an experienced team of producers with an expansive global network.
The Festival of Biologics is your opportunity to hear from industry leaders, global regulators and world-renowned academics at the forefront of innovation. Join us for 3 days of cutting-edge insights into the latest industry developments.
Basel, 15 - 17 October 2024
Schedule
Create your personal agenda –check the favourite icon
Opening Plenary Presentation
Senior Representative, Roche
Title TBA
Senior Representative, GeneData
Antibody-based product successes and progresses in 2024
Biosimilar Development at Pfizer
Bispecific antibodies and antibody fusion proteins for cancer immunotherapy
Trial Design and Management at Diachi Sanko
Title TBA
Senior Representative, FUJIFILM Diosynth
Advanced LC MS/MS Workflows for HCPs Quantification
Advances in pHLA directed T cell engager discovery and design
Antibody-cytokine fusions for cancer therapy
Generative Models for Antibody variant generation: the good, the bad, and the ugly
New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)
The Tubutecan Platform : Technology Enabled Payload Solutions Targeting Topoisomerase-I & Dual payload ADCs
Title TBA
Understanding Cellular and Molecular Players in T Cell Bispecific antibody (TCB)-mediated Cytokine Release Syndrome (CRS)
Using E. coli to map and understand protein aggregation landscapes
Small Molecule Therapeutics targeting Fibroblast Activation Protein in the tumor microenvironment
T cell coengineering strategies for cancer immunotherapy
Title TBA
Senior Representative, Carterra
Title TBA
Senior Representative, Genovac
Title TBA
Senior Representative, ATUM
Title TBA
Senior Representative, XTALPI
Title TBA
Senior Representative, ATUM
Understanding the T cell adaptation to the tumour microenvironment to improve CAR-T therapy
A critical look at acid-catalyzed deamidation, peptide solubility and other challenges in conventional Multi-Attribute Method (MAM) workflows – potential pitfalls and solutions
A Phase 3 personalized vaccine platform technology for cancer and infectious disease
BiXAb MAIT engagers: redirecting an abundant cytotoxic T-cell subset to control solid tumors.
Harnessing innate immunity in cancer therapy
Mammalian Antibody Display & Secretion for Microfluidic Hit Discovery
Title TBA
Senior Representative, Selvita
Title TBA
Unraveling IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Target: Harnessing the Power of AI and Big Data
Caibin Sheng, Data scientist, machine learning, computational oncology, GV20 Therapeutics (RESERVED)
5 Elements for Successful Biologics/Biosimilars Development – The CDMO Perspective
Thebiologics CDMOMarket size is expected to grow from USD 13.58 billion in 2023 to USD 24.77 billion by 2028, at a CAGR of 12.78%. This growth is primarily driven by significant increase in outsourcing development and manufacturing activities by biotech as well as small and medium-sized pharmaceutical companies, to accelerate their biologic assets (e.g. bispecifics, mAbs and other recombinant proteins) into clinic and avoid the investment risk in capital-intensive manufacturing facilities. To stay competitive, biologics CDMO require not only high technical capability and globally compliant manufacturing facilities, but also unmatched agility and customer advocacy in their DNA to drive desired outcomes for their clients.
This talk will cover the 5 essential and fundamental elements (with examples), that are required for any CDMO to successfully deliver client programs and help them evolve from a mere service provider to a true value partner.
BPT567, a first-in-class PD1-IL18 immunocytokine
Cancer immunotherapy using bispecific gamma delta T cell engagers
Engineering a protein-based cervical cancer vaccine with dual properties
Enhancing efficacy of CAR T-cells against solid tumours by optimising CAR structure
Robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds
Title TBA
Senior Representative, Genscript Probio
Title TBA
Senior Representative, Sapio Life Sciences
Tripokin: Best-in-Class potential for tumor targeted Interleukin-2 (IL2) potentiated by Tumor Necrosis Factor (TNF)
Advancing a novel linker technology
Artificial intelligence methods to detect dengue-specific antibody repertoire and sequence patterns
CB307: A novel T-cell costimulatory Humabody VH therapeutic for PSMA-positive tumors
Immune evaluation of glioblastoma patients: peripheral blood phenotypes resemble tumor-infiltrating cell phenotypes
Sane in the membrane - Discovery of antibodies against challenging membrane protein targets using Salipro nanoparticles
Stem cell based gene therapy for Recombinase deficient-SCID
ANV600: a uniquely engineered, cis-signaling, anti-PD-1/IL-2 bispecific antibody that effectively expands stem-like and effector CD8 T cells in the tumor microenvironment
Engineering of human cytokines as novel drugs
Immune Secretomes Targeting Age-Acquired Immune Decline
Native Chemokine Receptor Complexes in Salipro Nanoparticles Enable Development of Next Generation Therapeutics
Recent Updates in Biosimilar Regulation
Title TBA
Title TBA
TOPO1i ADC Platform, From Concept to Pipeline Applications
Why do 95% of oncology drugs fail in clinical development?
A novel symmetric bispecific antibody format by engraftment of cattle-derived knob paratopes into the IgG1 Fc region
Delivery unique functionality in bispecific antibodies
Mammalian display at the heart of antibody engineering
Title TBA
Senior Representative, Veraxa
Title TBA
Senior Representative, Lonza
Title TBA
Title TBA
Using single-cell RNA at scale to dissect fibroblast biology identifies CTHRC1 as a novel highly selective antibody target in cancer and fibrosis
Accelerating T cell therapy development through collaboration and real-time characterization
ATACs as New Therapeutic Modality to Fight Cancer
Senior Representative, Heidelberg Pharma
Tertiary Lymphoid Structures: New Biomarker and Target for Cancer Immunotherapy
Title TBA
Senior Representative, Icosagen
Title TBA
Senior Representateive, OMNIAB
Title TBA
Senior Representative, Lonza
Discovery and optimisation of common light chain Fabs for the generation of multispecific antibody therapeutics based on the Ichnos BEAT® platform
The design of potent multispecific immune cell engager based on the Ichnos BEAT® platform relies on the identification of diverse and developable common light chain (cLC) Fabs. The Ichnos discovery engine will be presented: cLC Fab discovery by phage and mammalian display; screening for optimal affinity, specificity and developability and automated architecture exploration based on functional screening. The design, generation and validation of a state-of-the-art antibody phage display library as a source of diverse cLC Fab will be highlighted.
Linker matters: Highly stable and efficient ADCs made with native antibodies and peptide linkers
Next iteration in cytotherapy technologies
Title TBA
Title TBA
Create your personal agenda –check the favourite icon
Roundtables
Senior Representative, GeneData
Overcoming the tumour microenvironment for effective immunotherapy Opportunities and challenges with multiplex immunofluorescence technologies for immunotherapy A new era of autoimmune disease treatment using mRNA Challenges in Immunotherapy Clinical Trial Design Advances in allogenic cell therapy Biomarkers in Translational Medicine Sustainability of the industry Pipeline development The impact of Interchangeability on biosimilar development Embedding the patient voice in clinical trial design Site Relationships Formulation development strategies Drug Substance Development StrategiesFinance & Investment for Start Ups - Panel Discussion
IOS-1002-A novel multitarget therapeutic modulating 3 checkpoint pathways to activate both adaptive and innate immunity
One-shot optimization of antibody/protein scaffolds by in-silico computational approaches
Taking the characterization of therapeutic antibodies and derivates with LC-MS to the next level by improving MS compatibility, speed and selectivity
Title TBA
Senior Representative, University of Sheffield
Title TBA
MY006: allergen-targeted antibodies for the treatment of peanut allergy
Title TBA
Senior Representative, Q2 Solutions
Title TBA
Senior Representative, Sphere Fluidics
Title TBA
Senior Representative, Bio-Techne
Title TBA
Senior Representative, Twist Bioscience
BYON4228, a clinical stage potentially best-in class anti-SIRPα antibody for promoting antibody-mediated tumor elimination
Targeting the inside of cells with biologicals
Translational development of a non-mAb protein
Combinatorial assembly of bispecific antibodies by modular, in vitro protein-protein-conjugation
Finance & Investment Q+A - Ask the Investors
JJP-1008, a novel checkpoint inhibitor for cancer treatment: Correct the patient’s immunosuppressive TME
Panel Discussion: How Can We Achieve a Long-Term Sustainable Biosimilars Market?
Title TBA
Senior Representative, Excell Gene
Title TBA
Senior Representative, Refeyn
Improved cell line development techniques for recombinant protein production
Superior antiviral antibodies from cognate recombinant antibody repertoires of human donors
The influence of DM1, MMAE, and MMAF on biodistribution and pre-clinical therapeutic efficacy of affibody-based drug conjugates
Title TBA
Developing peptide barcoded antibodies for precision medicine
Mammalian highthroughput expression platform (mHTX) for protein reagent generation and beyond
This presentation will cover:
· Introduction to the mHTX process that allows for design, generation, and expression tests of hundreds of constructs in parallel, followed by purification screen for selected panel of up to 96 molecules.
· Challenges encountered while developing robust, high-throughput and automation friendly methodologies as well as data capture solutions enabling efficient data mining and reuse.
· Examples how mHTX was instrumental for delivering both secreted and membrane protein reagents as well as identifying optimal constructs for cellular reagents generation.
Systems biology approaches in improving quality and titer of biologics
Title TBA
Title TBA
Accelerating Early Discovery Through HTP and High-Speed Antibody Production
Development of NANOBODY® therapeutics for the treatment of hematological diseases
Optimised bioprocessing aids for manufacturing biotherapeutics
Bioprocessing aids such as surfactants play a key role in maximising the output of production cell lines,alongside their importance in producing and maintaining a safe, efficacious, and high purity drug substancethroughout the downstream process. In this talk we shall discuss how Croda Pharma has developed andoptimised specific surfactants for upstream processing to insure consistency in performance and quality. Indownstream we will demonstrate how surfactants can be used for processes such as viral inactivation, cell lysis, antibody stability and purification. Learn more about the cutting-edge advancements that set CrodaPharma apart as an integral supplier to the biopharmaceutical industry, helping us to empower biologicsdelivery.
Revisiting Biomarkers in Lupus Nephritis
In this presentation, we will revisit the spectrum of biomarkers for lupus nephritis (LN), evaluating traditional perceptions and exploring novel insights. Through a critical examination of both classical and emerging biomarkers we aim to enhance and refine accessible diagnostic strategies in LN management.
Title TBA
Senior Representative, Nanotemper
Title TBA
Senior Representative, Alloy Therapeutics
An automated transient transfection platform for the expression of complex, multispecific antibodies
Production of candidates, control molecules and targets at a preclinical stage is a critical activity for the development of therapeutic antibodies. Automation of certain processes (e.g., transfection, purification) can help achieve high protein production reproducibility and throughput to facilitate the identification of lead candidates. The Tecan Fluent liquid handling system was customized to perform automated transient transfection in 50-mL TubeSpin and plate formats. This platform is adapted for the transfection of complex, multispecific antibodies in the same run and led to improved titers compared to manual transfection.
Title TBA
Exploring the potential of single domain antibodies for cancer immunotherapies and imaging
Title TBA
Senior Representative, SGS
Title TBA
Title TBA
Create your personal agenda –check the favourite icon
Precision medicine – limitations and learnings in (ultra-)rare diseases
Trends over time in the development of non-standard antibody formats
Biosimilar Manufacturing
Characterizing the unpredicted
Functional screening of a soluble TCR format library identifies novel molecular architectures for redirected T cell killing
Immunogenicity has a complicated relationship with Self
Title TBA
Current Approach to Immunogenicity risk assessments for multi-specific and non-antibody scaffolds
Democratizing of cell-based therapies offering a benefit for patients globally
Gas phase stability of glyco-engineered therapeutic pentraxins
A Developability Screening Cascade to Advance Multi-specific Therapeutic Antibodies to the Clinic
The flexible BEAT® platform enables 5 or more functional modules to be combined into a single molecule. The biophysical properties of a complex multi-specific immune cell engager antibody can be quite different to the sum of its parts. Therefore, a developability screening cascade was developed starting from Fab or cytokine selection to multi-specific lead candidate selection. This was applied to identify ISB 2001, a first-in-class tri-specific BCMA and CD38 T cell engager now advancing in the clinic to treat Multiple Myeloma.
Immunotherapeutic targeting of Fibroblast Activation Protein (FAP) in treatment refractory Glioblastoma using novel CAR-T cell therapy
Title TBA
Panel Discussion: Biologics and the Patient: Delivering better access for oncology
- Meeting patient needs in development: personalised and precision medicine
- Access considerations in translational and clinical development
- Delivering the therapy to patients: patient involvement in bringing a product to market
Cost-saving potential of biosimilars
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events